Ocular Therapeutix (OCUL) Free Cash Flow (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Free Cash Flow of -$70.6 million for Q2 2026, down 25.06% year-over-year from -$94.3 million in Q2 2025, and little changed on a QoQ basis from -$70.7 million in Q1 2026.
Ocular Therapeutix (OCUL) Free Cash Flow (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Free Cash Flow for 14 years, with the latest figure at -$70.6 million in Q2 2026.
- Free Cash Flow for Q2 2026 came in at -$70.6 million, down 25.06% year-over-year; the trailing twelve-month figure through Jun 2026 was -$255.1 million (down 42.22% YoY), and the FY2025 annual result was -$216.9 million, down 59.52% from the prior year.
- Free Cash Flow held at -$70.6 million in Q2 2026, from -$70.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$8.0 million in Q3 2023 and troughed at -$70.7 million in Q1 2026.
- A 5-year average of -$35.2 million and a median of -$29.8 million in 2024 frame the typical range for Free Cash Flow.
- The widest annual swing landed in 2022, when Free Cash Flow jumped 43.67%; it then sank 358.62% in 2024.
- A 5-year view of Free Cash Flow shows it stood at -$19.1 million in 2022, then dropped by 19.91% to -$22.9 million in 2023, then plunged by 72.96% to -$39.6 million in 2024, then slumped by 44.05% to -$57.1 million in 2025, then fell by 23.74% to -$70.6 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$70.6 million in Q2 2026, -$70.7 million in Q1 2026, and -$57.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | -70.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -70.64 Mn |
| Jun 30, 2026 | -70.64 Mn |
| Mar 31, 2026 | -67.32 Mn |
| Mar 31, 2026 | -67.32 Mn |
| Dec 31, 2025 | -57.09 Mn |
| Dec 31, 2025 | -57.09 Mn |
| Sep 30, 2025 | -56.72 Mn |
| Sep 30, 2025 | -56.72 Mn |
| Jun 30, 2025 | -56.48 Mn |
| Jun 30, 2025 | -56.48 Mn |
| Mar 31, 2025 | -46.60 Mn |
| Mar 31, 2025 | -46.60 Mn |
| Dec 31, 2024 | -39.47 Mn |
| Dec 31, 2024 | -39.47 Mn |
| Sep 30, 2024 | -36.59 Mn |
| Sep 30, 2024 | -36.59 Mn |
| Jun 30, 2024 | -24.59 Mn |
| Jun 30, 2024 | -24.59 Mn |
| Mar 31, 2024 | -34.14 Mn |
| Mar 31, 2024 | -34.14 Mn |